Osmotica Pharmaceutical and Upstate Pharma, LLC, a Subsidiary of UCB, Inc., Announce the Availability of Venlafaxine Extended-Release Tablets

WILMINGTON, N.C.--(BUSINESS WIRE)--Osmotica Pharmaceutical Corp. is announcing that Venlafaxine Extended-Release Tablets, 37.5 mg, 75 mg, 150 mg, and 225 mg, which was approved by the U.S. Food and Drug Administration in May, is now commercially available through its marketing partner, Upstate Pharma, LLC, a subsidiary of UCB, Inc. Shipments of the product to wholesalers and other commercial outlets began September 30, 2008 and promotion of the product will commence later in the month. Forrest Waldon, CEO of Osmotica Pharmaceutical stated, “We are excited about the launch of this innovative product and look forward to a successful commercial relationship.”